Literature DB >> 20098425

Structural basis of respiratory syncytial virus neutralization by motavizumab.

Jason S McLellan1, Man Chen, Albert Kim, Yongping Yang, Barney S Graham, Peter D Kwong.   

Abstract

Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20098425      PMCID： PMC3050594          DOI： 10.1038/nsmb.1723

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN： 1545-9985            Impact factor:   15.369


  17 in total

1.  Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

Authors:  J Arbiza; G Taylor; J A López; J Furze; S Wyld; P Whyte; E J Stott; G Wertz; W Sullender; M Trudel
Journal:  J Gen Virol       Date:  1992-09       Impact factor: 3.891

2.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

3.  Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.

Authors:  Y Tao; S V Strelkov; V V Mesyanzhinov; M G Rossmann
Journal:  Structure       Date:  1997-06-15       Impact factor: 5.006

4.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

5.  Modelling the structure of the fusion protein from human respiratory syncytial virus.

Authors:  Brian J Smith; Michael C Lawrence; Peter M Colman
Journal:  Protein Eng       Date:  2002-05

6.  Shape complementarity at protein/protein interfaces.

Authors:  M C Lawrence; P M Colman
Journal:  J Mol Biol       Date:  1993-12-20       Impact factor: 5.469

7.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

8.  Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; V G Hemming
Journal:  Pediatrics       Date:  1995-04       Impact factor: 7.124

9.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

10.  Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; D Andreu; C Carreño; P Whyte; G Taylor; J A Melero
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891
View more
  84 in total

1.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Future opportunities for passive immunity against viral diseases.

Authors:  Barney S Graham
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

3.  Biomimetic monolayer-protected gold nanoparticles for immunorecognition.

Authors:  Kellen M Harkness; Brian N Turner; Amanda C Agrawal; Yibin Zhang; John A McLean; David E Cliffel
Journal:  Nanoscale       Date:  2012-05-29       Impact factor: 7.790

4.  Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Sarah A Kenward; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

5.  Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors:  Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

Review 6.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

7.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

Review 8.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

10.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.